Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IJDNB
ADC Name
PDL1-Dox ADC
Synonyms
PDL1 Dox ADC
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
Antibody Name
Atezolizumab
  Antibody Info 
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
  Antigen Info 
Payload Name
Doxorubicin
  Payload Info 
Therapeutic Target
DNA topoisomerase 2-alpha (TOP2A)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.25
uM
MDA-MB-231 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.25 uM Positive PDL1 expression (PDL1+++/++)
Method Description
The MTT-based cytotoxicity assay in MDA-MB-231 cells that displayed a dose dependent cell killing of PDL1-Dox treatment.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers (Basel). 2019 Feb 16;11(2):232. doi: 10.3390/cancers11020232.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.